ESA Biosciences Gets $500K From NIH to Develop Metabolomics Platform

NEW YORK, March 24 (GenomeWeb News) - The US National Institutes of Heath has awarded Chelmsford, Mass.-based ESA Biosciences $538,619 to support the development of technologies to study metabolomics, GenomeWeb News has learned.

The grant, named "Integrating Lcec/Lcm in a Single Metabolomics Platform," was awarded to the company as part of the NIH Roadmap for Medical Research initiative, the company said in a statement.

"We will work toward developing a rugged platform that will incorporate both MS and EC detection in parallel, communicating with each other, to produce results that individually would not be possible," Ian Acworth, ESA vice president of HPLC products and services, said in the statement. The research will also incorporate ESA's new, breakthrough HPLC detection technology, the Corona Charged Aerosol Detector, the company added.

The company will conduct its research in collaboration with Oak Ridge National Laboratory, Applied Biosystems/MDS SCIEX, Millennium Pharmaceuticals, Cornell University Medical School, MassachusettsCollege of Pharmacy, BostonUniversityMedicalSchool, and Burke Medical Research Institute, ESA said.